INCONGRUENT RESISTANCE TO AMINOGLYCOSIDES IN MULTIDRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS STRAINS
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Veröffentlicht: |
Zenodo
2025
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866902072203411456 |
|---|---|
| author | MOHD JASEEM, Khan |
| author_facet | MOHD JASEEM, Khan |
| contents | <p>Since the discovery of the bactericidal activity of aminoglycosides, streptomycin, kanamycin,</p> <p>amikacin, and capreomycin (a macrocyclic peptide) have been widely used to treat tuberculosis and</p> <p>multidrug-resistant (MDR) tuberculosis. In general practice, resistance to kanamycin is often used</p> <p>as the sole criterion for defining extensively drug-resistant tuberculosis, assuming that all other</p> <p>drugs in this group or related drugs are resistant to certain strains. However, the assumption of</p> <p>cross-resistance between drugs in the same group is not always true for Mycobacterium</p> <p>tuberculosis. This prompted us to conduct a study to determine the concordance resistance pattern</p> <p>between aminoglycosides and the macrocyclic peptide capreomycin.A total of 2383 mycobacterial</p> <p>strains isolated from suspected MDR cases were subjected to susceptibility testing with</p> <p>aminoglycosides (kanamycin and amikacin), the polypeptide capreomycin, and ofloxacin to</p> <p>determine the resistance pattern. Cultures and susceptibility testing were performed using an</p> <p>automated BACTEC MGIT 960 instrument. Positive susceptibility samples were confirmed by</p> <p>PCR.The results showed that, of the total 2383 strains, 844 (35.41%) were susceptible to all four</p> <p>drugs, and 1539 (64.58%) strains showed resistance in the form of multi- or mono-resistance. The</p> <p>results also showed that of the 474 kanamycin-resistant mycobacterial strains, 86.7% and 77.6%</p> <p>were resistant to amikacin and capreomycin, respectively. Conversely, of the 425 amikacin-</p> <p>resistant mycobacterial strains, 3.3% were susceptible to kanamycin. Our findings suggest that</p> <p>performing susceptibility testing for individual drugs within a class may not provide an accurate</p> <p>strain status and may not be sufficient to make clinical decisions. It is necessary to conduct</p> <p>susceptibility testing of all MDR-TB strains with all aminoglycoside and macrocyclic peptide drugs</p> <p>before subjecting patients to comprehensive drug therapy</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_14868929 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | INCONGRUENT RESISTANCE TO AMINOGLYCOSIDES IN MULTIDRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS STRAINS MOHD JASEEM, Khan Aminoglycosides <p>Since the discovery of the bactericidal activity of aminoglycosides, streptomycin, kanamycin,</p> <p>amikacin, and capreomycin (a macrocyclic peptide) have been widely used to treat tuberculosis and</p> <p>multidrug-resistant (MDR) tuberculosis. In general practice, resistance to kanamycin is often used</p> <p>as the sole criterion for defining extensively drug-resistant tuberculosis, assuming that all other</p> <p>drugs in this group or related drugs are resistant to certain strains. However, the assumption of</p> <p>cross-resistance between drugs in the same group is not always true for Mycobacterium</p> <p>tuberculosis. This prompted us to conduct a study to determine the concordance resistance pattern</p> <p>between aminoglycosides and the macrocyclic peptide capreomycin.A total of 2383 mycobacterial</p> <p>strains isolated from suspected MDR cases were subjected to susceptibility testing with</p> <p>aminoglycosides (kanamycin and amikacin), the polypeptide capreomycin, and ofloxacin to</p> <p>determine the resistance pattern. Cultures and susceptibility testing were performed using an</p> <p>automated BACTEC MGIT 960 instrument. Positive susceptibility samples were confirmed by</p> <p>PCR.The results showed that, of the total 2383 strains, 844 (35.41%) were susceptible to all four</p> <p>drugs, and 1539 (64.58%) strains showed resistance in the form of multi- or mono-resistance. The</p> <p>results also showed that of the 474 kanamycin-resistant mycobacterial strains, 86.7% and 77.6%</p> <p>were resistant to amikacin and capreomycin, respectively. Conversely, of the 425 amikacin-</p> <p>resistant mycobacterial strains, 3.3% were susceptible to kanamycin. Our findings suggest that</p> <p>performing susceptibility testing for individual drugs within a class may not provide an accurate</p> <p>strain status and may not be sufficient to make clinical decisions. It is necessary to conduct</p> <p>susceptibility testing of all MDR-TB strains with all aminoglycoside and macrocyclic peptide drugs</p> <p>before subjecting patients to comprehensive drug therapy</p> |
| title | INCONGRUENT RESISTANCE TO AMINOGLYCOSIDES IN MULTIDRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS STRAINS |
| topic | Aminoglycosides |
| url | https://doi.org/10.5281/zenodo.14868929 |